Blog

CME Group to List USD Eris Interest Rate Swap Futures

CME Group and Eris enter exclusive licensing deal to list Eris futures on CME in Q4 2018

CHICAGO, May 10, 2018 /PRNewswire/ — CME Group, the world’s leading and most diverse derivatives marketplace, and Eris Exchange, a U.S.-based futures exchange group that offers swap futures as the leading alternative to traditional over-the-counter (OTC) swaps, today announced they have entered into an exclusive licensing agreement to list USD Eris Interest Rate Swap futures, which already clear at CME Clearing.

Pending regulatory approval, Eris futures will be listed with and subject to the rules and regulations of CBOT, starting in the fourth quarter of 2018, and existing open interest in the contracts will be transferred to CME Group at that time. The Eris futures will trade alongside the MAC Swap Futures, bringing together the two leading interest rate swap futures on a single exchange venue. Until the migration in late 2018, Eris Swap Futures will remain listed at Eris Exchange and cleared at CME Clearing, where they are subject to margin offsets with CME Group’s interest rate futures.

Read more

F-Prime Capital Partners Announces Parker Moss as New Entrepreneur-in-Residence

CAMBRIDGE, Mass.–(BUSINESS WIRE)–F-Prime Capital Partners, a global venture capital firm focused on investments in life sciences, healthcare and technology, today announced that Parker Moss has joined the firm as entrepreneur-in-residence. Parker will be based in London and will focus on health technology investments and company-creation activities.

“We are excited to welcome Parker to the firm – he is an important addition to the F-Prime team,” said Stephen Knight, managing partner of F-Prime Capital Partners. “Parker’s experience as a senior executive in the healthcare and telecom industries, and his strong conviction and determination for transforming healthcare delivery, will be invaluable as we push further into building and investing in health technology companies. His hands-on experience on the frontline of both the hospital and the community sectors of the NHS has given him an acute sense of the barriers and opportunities for disruptive innovation in medical research, on the wards and in patients’ homes, and we look forward to working with Parker to bring some of these exciting opportunities to market.”

Read more

Buoy Health and CVS Health Provide Easy Access to Affordable Care

Buoy Health leverages advanced AI to help consumers nationwide to identify the right course of treatment, including access to care at MinuteClinic locations

BOSTON–(BUSINESS WIRE)–Buoy Health (www.buoyhealth.com), a health technology company that develops digital tools to help people from the moment they get sick to start their care on the right foot, today announced that it has entered into an agreement with CVS Health’s MinuteClinic subsidiary to provide patients with access to convenient, accessible and affordable care at any of its over 1,100 MinuteClinic locations nationwide. The relationship, which will be available to patients through www.buoyhealth.com later this year, will leverage Buoy’s advanced AI to help patients not only gain a more accurate assessment of what is wrong, but to help them get better faster by providing them with easy access to care at a nearby MinuteClinic, when appropriate.

Read more

OTA Insight listed on Analytics Insight ‘The 10 Most Valuable Business Intelligence Companies in 2018’

SAN JOSE, California and HYDERABAD, India, May 7, 2018 /PRNewswire/ —

Analytics Insight Magazine, a brand of Stravium Intelligence and an influential platform for big data, analytics and insights has named ‘The 10 Most Valuable Business Intelligence Companies in 2018‘ in its April-May issue.

 The issue features Altair as the Cover Story. Altair transforms design and decision-making by applying simulation, machine learning and optimization throughout product life cycles. The company’s broad portfolio of simulation technology and patented units-based software licensing model enables Simulation-Driven Innovation™ for its customers.
Read more

Science 2 Startup Symposium Convened Over 230 Academic Researchers, Venture Capitalists, Entrepreneurs, and Pharmaceutical Executives, Creating Connections that can Advance Scientific Innovation and Entrepreneurship

Symposium Exposed Academics to Investors and Executives Who Could Help Guide Them to the Next Level

CAMBRIDGE, Mass., May 04, 2018 (GLOBE NEWSWIRE) — Science 2 Startup, an invitation-only event, convened over 230 members of the biotech ecosystem at the Broad Institute of MIT and Harvard last week. Approximately half of the attendees were venture capital and other investors, a quarter were biopharma executives and entrepreneurs, and a quarter were the academic investigators and their technology transfer professionals from top research institutions.

Science 2 Startup was created and presented by Boston-area venture capital firms Atlas Venture, F-Prime Capital Partners, and SV Health Investors. The scientists and other academic representatives came from three countries and all over the US.

The agenda underscored the intensity of the biotech ecosystem and the relevance and interdependence of all of its players: scientists, entrepreneurs, the pharmaceutical industry, and funding sources.

Read more

Flywire and Billtrust Partner to Accelerate Cross-Border Account Receivables

Integrated solution lowers transaction fees, streamlines processing and enhances customer experience for Billtrust customers

BOSTON and HAMILTON, N.J., May 03, 2018 (GLOBE NEWSWIRE) — Flywire, a provider of global payment and receivables solutions, and Billtrust, the leader in B2B payment cycle management, today announced a partnership aimed at streamlining the receipt of international payments for Billtrust business customers. Billtrust users will receive an integrated solution that adds Flywire’s international payment processing and receivable capabilities to Billtrust’s automated invoice delivery and payment services. The joint offering will help these customers more easily collect international payments while lowering the cost of international wire fees and eliminating the manual posting of cross-border payments.

Billtrust’s cloud-based Quantum payment cycle management solution suite accelerates cash flow by automating invoice delivery, payments and cash application for businesses. Many of Billtrust’s customers also receive international payment wires. These transactions can be complex and include high transaction fees and foreign exchange costs for both the payer and receiver. The inability to accurately predict these costs can also result in short payments, increasing reconciliation costs for the biller while also negatively impacting customer satisfaction.

Read more

Orchard Therapeutics’ OTL-200 Receives Rare Pediatric Disease Designation from FDA for Treatment of Metachromatic Leukodystrophy

BOSTON and LONDON, May 03, 2018 (GLOBE NEWSWIRE) — Orchard Therapeutics, a leading commercial stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted a Rare Pediatric Disease Designation to the company’s gene therapy candidate OTL-200, for the treatment of patients with metachromatic leukodystrophy (MLD).

MLD is a rare, fatal, neurodegenerative, inherited metabolic disease caused by mutations in the ARSA gene. In its late infantile and juvenile forms, which represents the majority of MLD patients, mortality at 5 years is estimated at 75% and 30%, respectively1.

The FDA grants Rare Pediatric Disease Designations for serious or life-threatening diseases with manifestations in individuals aged from birth to 18 years, including access to the FDA’s expedited review and approval process. The Rare Pediatric Disease Designation makes the program eligible for a Rare Pediatric Disease Priority Review Voucher upon approval of OTL-200 by the FDA. OTL-200 was acquired by Orchard from GSK in April 2018 and originated from a pioneering collaboration between GSK and the Hospital San Raffaele and the Telethon Foundation, acting through their joint Telethon Institute for Gene Therapy, in Milan, initiated in 2010. This collaboration led to the development of Strimvelis, the world’s first approved autologous ex vivo gene therapy product. Orchard anticipates filing OTL-200 for market authorization with regulatory authorities from 2019.

Read more

Lumere, AHVAP Announce Partnership to Highlight Best Practices in Managing Care Variation

CHICAGO — Lumere, a leading provider of data-driven analytics, evidence and expert guidance to help health systems reduce unwarranted clinical variation, today announced plans to collaborate with the Association of Healthcare Value Analysis Professionals’ (AHVAP) Industry Business Education Collaborative agreement.

This agreement includes educational offerings highlighting best-practice strategies and tactics to help health systems and value analysis professionals consistently apply evidence to clinical decisions. “Hospitals and clinicians are strapped to find the time and the resources to collect the vast amounts of available drug and device information and also to dissect and separate unbiased sources from biased ones,” said Lumere Chief Development Officer Gina Thomas, RN, MBA. “AHVAP is the perfect collaborator because of its dedication to applying a clinical and evidence-based perspective to the clinical decision process.”

According to AHVAP President Susan Knapp, RN, MS, CVAHP, the two organizations share a vision to improve patient value by reducing unnecessary clinical variation and reducing costs. “Variation in care is a major contributor to wasteful healthcare spending,” she said. “Our members have the potential to play important roles in curtailing that waste, and solutions like Lumere’s offer important resources for them and their facilities.”

Read More

Innovent Biologics completed US $150 million Series E round financing

HONG KONG, April 26, 2018 /PRNewswire/ — Innovent Biologics, Inc., a leading biotech company in China, is pleased to announce the completion of its US$150 million Series E round financing.

This round of financing attracted high quality global institutional investors and biotech-focused funds.  Capital Group Private Markets (CGPM) is part of U.S.-based Capital Group Companies, one of the world’s largest and most successful investment organizations, and led this round with a US$90 million investment. Nick Chen, Partner of CGPM, joined Innovent’s Board of Directors.

 New investors including Cormorant Asset Management, Rock Springs Capital and Ally Bridge Group as well as the existing investors such as Temasek, Hillhouse, Legend Capital, Lilly Asia Venture and Taikang Insurance participated in this round. The proceeds will be used to speed up and expand the company’s clinical programs and build a capable commercial team to promote its emerging pipeline of products.

Read more

Orchard Therapeutics Expands US Presence with New Corporate Office in Boston

BOSTON and LONDON, April 24, 2018 (GLOBE NEWSWIRE) — Orchard Therapeutics, a leading commercial and clinical-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the opening of a new U.S. office in Boston’s Seaport District.

The new Boston office builds upon the company’s footprint in London as well as Foster City and Menlo Park, California. Orchard’s Boston office will become the company’s hub for its commercial operations and several key financial and administrative functions to support the rapidly expanding global organization.

“The opening of our Boston office represents a significant milestone in the growth and global expansion of Orchard Therapeutics” commented Mark Rothera, president and CEO of Orchard. “We look forward to joining the thriving biotechnology and academic communities in Boston, Cambridge and the surrounding area. The area has a deep pool of talent with complementary capabilities to help us realize our vision of becoming a global, fully integrated company transforming the lives of patients with rare diseases.”

Read more